What's new? Log in Free sign up

Catalyst Pharmaceuticals (CPRX) News and press releases

Company Profile

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $24 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Andrew Fein reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and maintains $24 price target.

Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales.

Catalyst Pharmaceuticals: Q1 Earnings Insights

Catalyst Pharmaceuticals Q1 Adj. EPS $0.41 Beats $0.32 Estimate, Sales $85.37M Beat $81.62M Estimate

Earnings, Earnings Beats, Earnings Misses, News, Small Cap

Catalyst Pharmaceuticals (NASDAQ: CPRX) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.32 by 28.12 percent. This is a 241.67 percent increase over earnings of $0.12 per share from the same period last year.

Earnings Scheduled For May 10, 2023

Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earnings at $0.42 per share on revenue of $851.81 million.

Catalyst Pharmaceuticals Announces Third-Party Abstracts On FYCOMPA® To Be Presented At The Upcoming American Academy Of Neurology 2023 Annual Meeting

Biotech, News, FDA, Events, General

Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients

Analyst Expectations for Catalyst Pharmaceuticals's Future

Analyst Ratings

4 Analysts Have This to Say About Catalyst Pharmaceuticals

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $24 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Andrew Fein reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and maintains $24 price target.

Why Catalyst Pharmaceuticals Shares Are Moving

Earnings, News, Small Cap

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading higher by 9.66% to $15.72 Thursday morning after the company reported better-than-expected fourth-quarter results.

Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed

Catalyst Pharmaceuticals Q4 EPS $0.31 Beats $0.21 Estimate, Sales $60.76M Beat $58.09M Estimate

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.21 by 47.62 percent. This is a 244.44 percent increase over earnings of $0.09 per

Earnings Scheduled For March 15, 2023

Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.

Earnings Outlook For Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Announces A Recent Third-Party Publication In Peer-Reviewed Journal Epilepsia Showing Perampanel Demonstrated High Efficacy In Patients With Rare Genetic Epilepsies

Biotech, News, FDA, General

Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for

Press releases

From Benzinga Pro

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

News, Management, Press Releases

CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and

Thinking about buying stock in JetBlue Airways, Hecla Mining, Catalyst Pharmaceuticals, Energy Transfer, or Ford?

Small Cap, Opinion, Press Releases

NEW YORK, May 15, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JBLU, HL, CPRX, ET, and F.

Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year

Earnings, Press Releases

Reports Record Total Revenues of $85.4 Million for Q1 2023 Delivers Revenue Growth of 98%, a Record Increase YoY GAAP EPS Diluted of $0.26 Per Share; a 117% Increase YoY Non-GAAP EPS Diluted of $0.41 Per Share, an

Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day

Health Care, Press Releases

Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third Quarter of 2023 CORAL GABLES, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals,

Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report

Analyst Ratings, Press Releases

CORAL GABLES, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and

Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023

News, Press Releases

CORAL GABLES, Fla., April 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing

Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting

Biotech, News, Health Care, Press Releases, General

CORAL GABLES, Fla., April 20, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Biotech, Earnings, Press Releases, General

Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million, a 59% YoY Increase Newly Acquired FYCOMPA® Product Expected

Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies

Health Care, Press Releases, General

CORAL GABLES, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.